ALGS · Company research

Aligos Therapeutics, Inc. Common Stock (ALGS): Valuation Analysis

Available valuation snapshots and ratios; unavailable metrics remain blank.

RESEARCH CONTEXT

Understand the numbers

Available valuation snapshots and ratios; unavailable metrics remain blank. Use period, currency, units and source fields when interpreting values.

1records availableHealthcare

Valuation Analysis data

Database-backed records only

1 rows
valuation datepricemarket capenterprise valuepeforward pepegprice salesprice bookprice fcf
Oct 8, 20265.38$57,473,752.0827092752.081.8413793103448276———1.8025891381257057—

Informational research only, not financial advice. Forecasts are uncertain and can be wrong.